Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, Agaricus blazei Murill

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 113-118

  Fujimiya, Yoshiaki ^a,b   Suzuki, Youichi ^a   Katakura, Ryuichi ^a   Ebina, Takusaburo ^a  

^a MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Osaka Forestry Office   (Japan)

Author keywords

Agaricus blazei; Double grafted tumor system; Immunosuppressive acidic protein; Proteoglucan; Selective tumoricidal activity

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE ACID PROTEIN;

AGARICALES; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASIDIOMYCETES; CANCER INHIBITION; CELL ACTIVATION; CELL MIGRATION; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PURIFICATION; DRUG SPECIFICITY; DRUG STRUCTURE; FUNGUS; GRANULOCYTE; INTRATUMORAL DRUG ADMINISTRATION; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; AGARICUS; ANIMALS; ANTINEOPLASTIC AGENTS; GLUCANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0032925054     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Cragg GM, Newman DJ and Snader KM: Natural products in drug discovery and development. J Nat Prod 60: 52-60, 1997.
2. Williams DL, Pretus HA, MeName RB, Jones EL, Ensley HE, Browder IW and Di Kuzio NR: Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyeces cerevisiae. Immunopharmacology 7: 139-155, 1991.
3. Chen MD, Paley PJ, Potish RA and Twiggs LB: Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 67: 131-136, 1997.
4. Fox BW: Medicinal plants in tropical medicine. Natural products in cancer treatment from bench to the clinic. Trans R Soc Trop Med Hyg 85: 22-25, 1991.
5. Seljelid R, Figenschau, Bøgwald L, Rasmussen LT and Austgulen R: Evidence that tumour necrosis induced by aminated β1-3D polyglucose is mediated by a concerted action of local systemic cytokines. Scand J Immunol 30: 687-694, 1989.
6. Takeda Y, Tanaka M, Miyazaki H, Takeo S, Nomoto K and Yoshikai Y: Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccaride SPR-901. Cancer Immunol Immunother 38: 143-148, 1994.
7. Itoh H, Itoh H, Amano H and Noda H: Inhibitory action of a (1 →6-β-D-glucan complex (FIII-2-b) isolated from Agaricus blazei Murill ("Himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. Jpn J Pharmacol 66: 265-271, 1994.
8. Fujimiya Y, Suzuki Y, Oshiman K, Kobori K, Moriguchi K, Nakashima H, Matumoto Y, Takahara S, Ebina T and Katakura R: Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother 46: 135-147, 1998.
9. Ebina T, Murata K and Tamura K: Antitumor effect of intradermal administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of α1-acid glycoprotein, in mice. Jpn J Cancer Res 85: 93-100, 1994.
10. Olson E, Standing JE, Griego-harper N, Hoffman OA and Limper AH: Fungal β-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages. Infection and Immunity 64: 3548-3554, 1996.
11. Hoffman OA, Olson EJ, Limper AH: Fungal β-glucan modulates macrophage release of tumor necrosis factor-α in reponse to bacterial lipopolysaccaride. Immunol Lett 37: 19-25, 1993.
12. Sveinbjørnsson B, Olsen R, Seternes OM and Seljelid: Macrophage cytotoxicity against murine MethA sarcoma involves nitric oxide-mediated apoptosis. Biochem Biophys Res Commun 223: 643-649, 1996.
13. Fujimiya Y, Kobori, H, Oshiman K, Soda R and Ebina T: Tumoricidal activity of high molecular weight polysaccarides derived from Agaricus blazei via oral administration in the mouse tumor model. Jpn Food Sci Eng (Nippon Shokuhin Kogaku Kougakkai) 45: 246-252, 1998.
14. McGuire WP: Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 51: 78-85, 1993.
15. Holmes FA, Walters RS, Theriault RL, Foramn AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
16. Legha SS, Ring S, Padadopoulos N, Raber M and Benjamin RS: Phase II study of paclitaxel in metastatic melanoma. Cancer 65: 2478-2481, 1990.
17. Pandey RC, Yankov LK, Poulev A, Poulev A, Nair R and Caccamese S: Synthesis and separation of potential anticancer active dihalocephalomannine diastereomers from extracts of Taxus yunnanenxis. J Nat Prod 61: 57-63, 1998.